Jones Day is a global law firm with more than 2,500 lawyers across five continents. The Firm is distinguished by a singular tradition of client service; the mutual commitment to, and the seamless collaboration of, a true partnership; formidable legal talent across multiple disciplines and jurisdictions; and shared professional values that focus on client needs.
The U.S. House of Representatives has passed a bill introduced by Reps. Joe Pitts (R-Pa.), Gene Green (D-Texas), and Frank Pallone (D-N.J.), the Improving Regulatory Transparency for New Medical Therapies Act.
United StatesFood, Drugs, Healthcare, Life Sciences
The U.S. House of Representatives has passed a bill introduced
by Reps. Joe Pitts (R-Pa.), Gene Green (D-Texas), and Frank Pallone
(D-N.J.), the Improving Regulatory Transparency for New Medical
Therapies Act. The bill requires the Drug Enforcement Agency
("DEA") to schedule new drugs within 90 days after the
later of the FDA's approval of the drug or the DEA's
receipt of FDA's scheduling recommendation. The legislation
also prescribes a timeline for DEA to register controlled
substances for use in clinical trials.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
